Skip to main content
Erschienen in: Cardiovascular Diabetology 1/2022

Open Access 01.12.2022 | Original investigation

Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China

verfasst von: Zhu Li, Yuanyuan He, Shuo Wang, Lin Li, Rongrong Yang, Yijia Liu, Qi Cheng, Lu Yu, Yanchao Zheng, Hongmei Zheng, Shan Gao, Chunquan Yu

Erschienen in: Cardiovascular Diabetology | Ausgabe 1/2022

Abstract

Background

The triglyceride glucose (TyG) index serves as a surrogate indicator of insulin resistance. However, there is limited evidence on the association between the TyG index and carotid artery plaque (CAP) in patients with coronary heart disease (CHD).

Methods

The 10,535 CHD patients were divided according to TyG index quartiles (Q1: TyG index < 8.52; Q2: 8.52 ≤ TyG index < 8.93; Q3: 8.93 ≤ TyG index ≤ 9.40; Q4: TyG index > 9.40). The presence or absence of CAP was determined by carotid ultrasonography. Logistic regression was used to analyze the relationship between the TyG index and CAP in CHD patients. The relationship between the TyG index and CAP in according to sex, age groups, and glucose metabolism states were also assessed.

Results

The baseline analysis showed that there were significant differences in related parameters among CHD patients divided into four groups according to the quartile of the TyG index. In the multi-adjusted modles, compared to Q1 of the TyG index, the odds ratios (OR) for Q4 of the TyG index for CAP were 1.37 (95% confidence interval [CI] 1.28–1.47) in CHD patients. The association between the TyG index and CAP in female (OR: 1.35; 95% CI 1.29–1.43) was higher than that in male (OR: 1.20; 95% CI 1.13–1.27). The OR value of middle-aged (≤ 60 years old) patients (OR: 1.34; 95% CI 1.26–1.42) was higher than that in elderly (> 60 years old) patients (OR: 1.16; 95% CI 1.11–1.22). In different glucose metabolism states, the TyG index of CHD patients was significantly related to the risk of CAP, with the highest OR value observed for diabetes (OR: 1.36; 95% CI 1.26–1.46).

Conclusions

The TyG index and CAP showed a significant association in CHD patients. This association between TyG index and CAP in CHD patients is higher in female than in male, and the association in middle-aged and elderly patients is higher than that in elderly patients. In the condition of DM, the association between TyG index and carotid artery plaque in CHD patients is higher.

Graphical abstract

Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12933-022-01470-3.
Zhu Li and Yuanyuan He are co-first authors

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
TyG
Triglyceride glucose
CHD
Coronary heart disease
DM
Diabetes mellitus
NCD
Non-communicable diseases
T2DM
Type 2 diabetes
CAD
Coronary artery disease
CAP
Carotid artery plaque
CIMT
Carotid artery intima-media thickness
Pre-DM
Prediabetes
AS
Atherosclerosis
SBP
Systolic blood pressure
DBP
Diastolic blood pressure
FPG
Fasting plasma glucose
TC
Total cholesterol
HDL-C
High-density lipoprotein cholesterol
TG
Triglycerides
LDL-C
Low-density lipoprotein cholesterol
CRP
C-reactionprotein
HbA1c
Glycated haemoglobin
OR
Odds ratios
CIs
Confidence intervals
HOMA-IR
Homeostasis model assessment of insulin resistance
SA
Subclinical atherosclerosis

Background

Coronary heart disease (CHD) is a class of chronic noncommunicable diseases (NCD) with extremely high incidence and mortality rates. Diabetes mellitus (DM) usually coexists with arterial hypertension and dyslipidemia [1, 2]. Type 2 diabetes mellitus (T2DM) accounts for 95% of all the diseases diagnosed with DM. Which is one of the risk factors for coronary artery disease (CAD) and the progression and rupture of atherosclerotic plaques [3]. CAD is also a common comorbidity and major cause of death in DM patients. Studies have shown that in participants without CHD history, T2DM is associated with carotid artery plaques (CAP), which is a better predictor than high carotid artery intima-media thickness (CIMT) or recurrent cardiovascular events [4]. Pre-DM patients have a high propensity for developing DM [5]. Many studies have reported that CHD patients have a higher risk of adverse prognosis in Pre-DM and glucose metabolism disorders [68].
The triglyceride glucose (TyG) index is a valuable biomarker for the development of diabetes and is used as a marker of insulin resistance (IR), leading to the occurrence of NCD [9, 10]. The TyG index is related to the high prevalence of CAD, while the increased risk of major adverse cardiovascular and cerebrovascular events (MACEs) [11, 12], including ischemic stroke [13], increased arterial stiffness [1416], hypertension [17], coronary artery stenosis [18], and carotid atherosclerosis (AS) [19] are related to the morbidity. However, no relevant studies have investigated the association between the TyG index and CAP in CHD patients according to their glucose metabolism statuses.
Therefore, this study aimed to clarify the association between the TyG index and CAP in the different glucose metabolic statuses of CHD patients, and to further investigate the association of TyG index and CAP in the different stratification of gender and age. In the clinical treatment of CHD, there is a need to identify simple biochemical indicators to prevent the risk of AS (such as CAP).

Methods

Patients

This large-scale, multi-center retrospective cohort study included 107,301 CHD inpatients who were admitted to six hospitals in Tianjin between January 1, 2014, and September 30, 2020. The root investigation study design excluded patients aged less than 35 years or older than 80 years, patients with tumor, infectious, or severe liver or kidney disease, and patients lacking data on triglyceride (TG), fasting plasma glucose (FPG), and carotid ultrasound measurements. A total of 10,535 participants were eventually included in the study. A flowchart of the patients recruitment was shown in Fig. 1. This study was approved by the ethics committee of Tianjin University of Traditional Chinese Medicine (TJUTCM-EC20190008) and registered with the Chinese Clinical Trial Registry (ChiCTR-1900024535) and ClinicalTrials.gov (NCT04026724).

Data collection

In this study, age, sex, smoking, drinking, and medication history of patients were recorded using standard structured questionnaires [20, 21]. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured by experienced technicians at the heart level using automatic blood pressure monitors. SBP ≥ 130 mmHg or DBP ≥ 80 mmHg was defined as hypertension [22].
Fasting venous blood samples were collected early in the morning from all participants. FPG, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), TG, low-density lipoprotein cholesterol (LDL-C), C-reactionprotein (CRP), and glycated haemoglobin (HbA1c) leves were measured using an automatic haematology analyzer. Standard laboratory procedure for quality control were strictly followed [23]. The TyG index was calculated as Ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2] [24]. Hyperlipidemia was defined as TC ≥ 6.2 mmol/L (240 mg/dL), TG ≥ 2.3 mmol/L (200 mg/dL), LDL-C ≥ 4.1 mmol/L (160 mg/dL), or HDL-C ≤ 1.0 mmol/L (40 mg/dL) [25]. Normal glucose tolerance (NGT) was defined as FPG < 5.6 mmol/L or HbA1c < 5.7%, Pre-DM was defined as FPG 5.6–6.9 mmol/L or HbA1c of 5.7–6.4%, DM was defined as FPG ≥ 7.0 mmol/L or HbA1c ≥ 6.5% [26].
The carotid ultrasound examinations were performed by a certified professional technician using a diagnostic ultrasound system. In B-mode imaging, the common carotid artery, internal carotid artery, and carotid artery bifurcation were scanned and imaged. CIMT was defined as the average IMT value of the left and right common carotid arteries [27]. Professional doctors analyzed the color of the carotid artery based on Doppler ultrasound results and recorded the number of CAPs and echo characteristics. CAP cases were divided into single (n = 1) and multiple (n ≥ 2). The echogenic properties of the CAP were categorized as hypoechoic, isoechoic, hyperechoic, and mixed types. This study employed rigorous quality control procedures to maintain consistency in the monitoring and test image acquisition and analysis. The inter-laboratory quality was assessed by licensed experimenters.

Statistical analyses

The characteristics of the participants in the different groups were compared using χ2 tests and Kruskal–Wallis H tests. Odds ratios (ORs) and 95% confidence intervals (CIs) of CAP were estimated for the TyG index using logistic regression. Age, sex, SBP, DBP, CRP, HbA1c, TC, HDL-C, LDL-C, smoking, drinking, hypertension, hyperlipidemia, use of antihypertensives, and use of antilipidemic were considered as potential confounders in this association. The collinearity of the different models was tested before logistic regression. Missing values were imputed using the multiple imputation method. All statistical analyses were performed using SPSS 24.0 (IBM Corp, New York, NY, USA).

Results

Baseline characteristics

The basic characteristics of the study population of 10,535 cases are shown in Table 1. The median age of the participants was 64 years old, and the proportion of female (51.4%) was slightly higher than that of male (48.6%). Among them, 8079 (76.69%) patients had CAP, while the highest proportion of DM patients was 37.6%. The subjects were divided into four groups according to the quartile level of the TyG index. Generally speaking, DBP, SBP, FPG, TC, TG, HbA1c, smoking, drinking, hyperlipidemia, use of antihypertensives, and use of antilipidemic were positively associated with the quartile level of the TyG index, while HDL-C was negatively associated with the quartile level of the TyG index.
Table 1
General characteristics of the study participants according to the TyG index
Characteristic
Total (N = 10,535)
TyG index
P-value
Q1 (n = 2650)
Q2 (n = 2647)
Q3 (n = 2590)
Q4 (n = 2648)
Sex, n (%)
 < 0.001
 Male
5121 (48.6)
1375 (51.9)
1256 (47.4)
1183 (45.7)
1307 (49.4)
 
 Female
5414 (51.4)
1275 (48.1)
1391 (52.6)
1407 (54.3)
1341 (50.6)
 
Age, years, median (IQR)
     
 < 0.001
 Total
64.0 (59.0–70.0)
65.0 (60.0–71.0)
64.0 (59.0–69.0)
64.0 (59.0–69.0)
63.0 (57.0–68.0)
 
  ≤ 60
55.0 (51.0–58.0)
55.0 (51.0–58.0)
55.0 (52.0–58.0)
55.0 (52.0–58.0)
55.0 (51.0–57.0)
 
  > 60
67.0 (64.0–71.0)
68.0 (64.0–72.0)
67.0 (64.0–71.0)
67.0 (63.0–71.0)
67.0 (64.0–71.0)
 
SBP, mmHg, median (IQR)
140.0 (128.0–156.0)
139.0 (124.0–152.0)
140.0 (126.0–155.0)
140.0 (130.0–159.0)
141.0 (130.0–159.0)
 < 0.001
DBP, mmHg, median (IQR)
83.0 (77.0–90.0)
80.0 (75.0–90.0)
82.0 (76.0–90.0)
83.0 (78.0–90.0)
84.0 (78.0–91.0)
 < 0.001
CRP, mg/L, median (IQR)
4.2 (2.0–12.8)
4.1 (1.9–14.9)
4.3 (2.0–14.2)
4.0 (2.0–11.3)
4.5 (2.2–11.2)
 < 0.001
FPG, mmol/L, median (IQR)
6.2 (5.3–8.1)
5.3 (4.8–5.9)
5.8 (5.1–6.8)
6.54 (5.6–8.1)
9.4 (7.0–12.6)
 < 0.001
LDL-C, mmol/L, median (IQR)
2.8 (2.1–3.4)
2.5 (1.9–3.1)
2.8 (2.2–3.4)
3.0 (2.3–3.6)
2.8 (2.2–3.5)
 < 0.001
HDL-C, mmol/L, median (IQR)
1.1 (0.9–1.3)
1.2 (1.0–1.4)
1.1 (0.9–1.3)
1.1 (0.9–1.2)
1.0 (0.8–1.1)
 < 0.001
TG, mmol/L, median (IQR)
1.4 (1.0–2.1)
0.9 (0.7–1.0)
1.3 (1.1–1.5)
1.8 (1.5–2.1)
2.6 (2.0–3.5)
 < 0.001
TC, mmol/L, median (IQR)
4.6 (3.8–5.4)
4.1 (3.4–4.9)
4.5 (3.8–5.2)
4.7 (4.0–5.5)
5.0 (4.2–5.7)
 < 0.001
HbA1c, mmol/L, median (IQR)
6.0 (5.6–7.0)
5.7 (5.4–6.2)
5.9 (5.5–6.5)
6.1 (5.6–6.9)
7.1 (6.1–8.6)
 < 0.001
TyG index
9.0 (8.5–9.4)
8.2 (8.0–8.4)
8.7 (8.6–8.8)
9.1 (9.0–9.3)
9.8 (9.6–10.2)
 < 0.001
Smoking, n (%)
4590 (43.6)
1173 (44.3)
1121 (42.3)
1101 (42.5)
1195 (45.1)
 < 0.001
Drinking, n (%)
5863 (55.7)
1457 (55)
1480 (55.9)
1421 (54.9)
1505 (56.8)
 < 0.001
Hypertension, n (%)
8875 (84.2)
2114 (23.8)
2201 (24.8)
2241(25.3)
2319 (26.1)
 < 0.001
Hyperlipidemia, n (%)
5770 (54.8)
690 (12.0)
961 (16.7)
1326 (23.0)
1981 (34.3)
 < 0.001
Use of antihypertensives, n (%)
5239 (49.7)
1160 (43.8)
1240 (46.8)
1363 (52.6)
1476 (55.7)
 < 0.001
Use of antilipidemic, n (%)
7787 (73.9)
1703 (64.3)
1947 (73.6)
2026 (78.2)
2111 (79.7)
 < 0.001
CIMT, mm, median (IQR)
0.10 (0.09–0.12)
0.10 (0.09–0.12)
0.10 (0.09- 0.12)
0.10 (0.09–0.12)
0.10 (0.09–0.12)
0.742
Carotid artery plaque, n (%)
8079 (76.69)
1985 (74.91)
1996 (75.41)
2006 (77.45)
2092 (79.00)
 < 0.001
Glucose regulation state, n (%)
 < 0.001
 Normal glucose regulation
3756 (35.7)
1735 (65.5)
1160 (43.8)
654 (25.3)
207 (7.8)
 
 Prediabetes
2813 (26.7)
694 (26.2)
861 (32.5)
834 (32.2)
424 (16.0)
 
 Diabetes
3966 (37.6)
221 (8.3)
626 (23.7)
1102 (42.5)
2017 (76.2)
 
No. of carotid artery plaque, n (%)
 < 0.001
 0
2456 (23.3)
665 (25.1)
651 (24.6)
584 (22.5)
556 (21)
 
 1
406 (3.9)
96 (3.6)
100 (3.8)
100 (3.9)
110 (4.2)
 
  ≥ 2
7673 (72.8)
1889 (71.3)
1896 (71.6)
1906 (73.6)
1982 (74.8)
 
Carotid artery plaque echo property, n (%)
 < 0.001
 Hypoechoic plaque
497 (4.7)
114 (4.3)
131 (4.9)
130 (5)
122 (4.6)
 
 Isoechoic plaque
548 (5.2)
137 (5.2)
133 (5)
136 (5.3)
142 (5.4)
 
 Hyperechoic plaque
4792 (45.5)
1211 (45.7)
1162 (43.9)
1194 (46.1)
1225 (46.3)
 
 Mixture plaque
2242 (21.3)
523 (19.7)
570 (21.5)
546 (21.1)
603 (22.8)
 
Data are presented as median (interquartile) or number (proportion, %)
Q1: TyG index < 8.52, Q2: 8.52 ≤ TyG index < 8.93, Q2: 8.93 ≤ TyG index ≤ 9.40, Q4: TyG index > 9.40
TyG, triglyceride-glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRP, C-reactionprotein; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycated haemoglobin; IQR, interquartile range

Association between the TyG index and the risk of carotid artery plaques

As shown in Table 2, in multivariate logistic regression analysis, when the TyG index was used as a continuous variable, it was significantly associated with the risk of CAP (OR: 1.29; 95% CI 1.24–1.34). The association between the TyG index and CAP was further explored using the TyG index as a categorical variable. Multivariate logistic regression analysis showed that the TyG index levels for Q3 and Q4 were associated with an increased OR for CAP when Q1 was used as a reference, with the highest association observed for Q4 (OR: 1.37; 95% CI 1.28–1.47). In both unadjusted and adjusted models, the TyG index (quartiles) was consistent with the P for trend of the CAP, when the TyG index was served as a continuous variable (P < 0.001). The association of TyG index with the number and echoproperties of carotid plaques were further evaluated. The results show that the association remained significant (Adittional file 1: Table S1–S2).
Table 2
Association between the TyG index and the risk of carotid artery plaques
Variables
Carotid artery plaques
OR (95% CI)a
P-value
OR (95% CI)b
P-value
OR (95% CI)c
P-value
TyG index
1.14 (1.11–1.17)
 < 0.001
1.28 (1.24–1.31)
 < 0.001
1.29 (1.24–1.34)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
1.00 (0.95–1.05)
0.969
1.10 (1.04–1.16)
0.537
1.01 (0.96–1.07)
0.682
Q3
1.09 (1.04–1.15)
0.001
1.22 (1.16–1.29)
0.013
1.07 (1.01–1.14)
0.025
Q4
1.22 (1.16–1.28)
 < 0.001
1.51 (1.43–1.59)
 < 0.001
1.37 (1.28–1.47)
 < 0.001
P-trend
 
 < 0.001
 
 < 0.001
 
 < 0.001
aModel 1: unadjusted
bModel 2: adjusted for sex, age, SBP, DBP
cModel 3: adjusted for sex, age, SBP, DBP, CRP, TC, HDL-C, LDL-C, smoking, drinking, hypertension, hyperlipidemia, use of antihypertensives, and use of antilipidemic
Regardless of sex, this relationship remained statistically significant after adjusting for variables. As shown in Table 3, after multivariate adjustment, the association between the TyG index and CAP in female (OR: 1.35; 95% CI 1.29–1.43), which was higher than that in male (OR: 1.20; 95% CI 1.13–1.27). As shown in Table 4, after multivariate adjustment, the TyG index of CHD patients was significantly associated with CAP at different ages. The OR value of middle-aged (≤ 60 years old) patients (OR: 1.34; 95% CI 1.26–1.42) was higher than that of elderly (> 60 years old) patients (OR: 1.16; 95% CI 1.11–1.22). For both sexes and different ages, using Q1 as the reference, Q4 was significantly related to the increased risks of CAP, even after multivariate adjustment, this relationship remained significant.
Table 3
Association between the TyG index and the risk of carotid artery plaques according to sex
Sex
Variables
Carotid artery plaques
OR (95% CI)a
P-value
OR (95% CI)b
P-value
OR (95% CI)c
P-value
Male
TyG index
0.94 (0.91–0.98)
0.003
1.14 (1.10–1.19)
 < 0.001
1.20 (1.13–1.27)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
1.00 (0.91–1.07)
0.789
1.13 (1.04–1.23)
0.004
1.05 (0.96–1.15)
0.268
Q3
0.95 (0.88–1.03)
0.213
1.17 (1.07–1.28)
 < 0.001
1.03 (0.94–1.13)
0.548
Q4
0.87 (0.80–0.94)
 < 0.001
1.23 (1.13–1.34)
 < 0.001
1.18 (1.06–1.31)
0.003
Female
TyG index
1.34 (1.30–1.39)
 < 0.001
1.38 (1.33–1.44)
 < 0.001
1.35 (1.29–1.43)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
1.08 (1.01–1.15)
0.019
1.08 (1.01–1.16)
0.031
0.99 (0.92–1.07)
0.875
Q3
1.31 (1.23–1.40)
 < 0.001
1.25 (1.17–1.34)
 < 0.001
1.10 (1.01–1.19)
0.019
Q4
1.62 (1.52–1.74)
 < 0.001
1.74 (1.61–1.87)
 < 0.001
1.52 (1.38–1.66)
 < 0.001
aModel 1: unadjusted
bModel 2: adjusted for age, SBP, DBP
cModel 3: adjusted for age, SBP, DBP, CRP, TC, HDL-C, LDL-C, smoking, drinking, hypertension, hyperlipidemia, use of antihypertensives, and use of antilipidemic
Table 4
Association between the TyG index and the risk of carotid artery plaques according to age
Age
Variables
Carotid artery plaques
OR (95% CI)a
P-value
OR (95% CI)b
P-value
OR (95% CI)c
P-value
 ≤ 60
TyG index
1.37 (1.32–1.42)
 < 0.001
1.27 (1.22–1.32)
 < 0.001
1.34 (1.26–1.42)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
1.19 (1.09–1.29)
 < 0.001
1.18 (1.08–1.30)
 < 0.001
1.05(0.95–1.16)
0.359
Q3
1.59 (1.45–1.73)
 < 0.001
1.45 (1.32–1.59)
 < 0.001
1.23 (1.11–1.37)
 < 0.001
Q4
1.90 (1.75–2.06)
 < 0.001
1.68 (1.54–1.83)
 < 0.001
1.54 (1.37–1.72)
 < 0.001
 > 60
TyG index
1.16 (1.12–1.21)
 < 0.001
1.21 (1.16–1.25)
 < 0.001
1.16 (1.11–1.22)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
0.99 (0.93–1.06)
0.840
1.05 (1.00–1.12)
0.170
0.98 (0.91–1.05)
0.563
Q3
0.99 (0.93–1.05)
0.720
1.07 (1.00–1.15)
0.040
0.95 (0.88–1.02)
0.161
Q4
1.23 (1.15–1.32)
 < 0.001
1.30 (1.21–1.39)
 < 0.001
1.15 (1.06–1.26)
0.002
aModel 1: unadjusted
bModel 2: adjusted for sex, SBP, DBP
cModel 3: adjusted for sex, SBP, DBP, CRP, TC, HDL-C, LDL-C, smoking, drinking, hypertension, hyperlipidemia, use of antihypertensives, and use of antilipidemic

Association between the TyG index and CAP according to glucose regulation state

As shown in Table 5, after multivariate adjustment showed significant associations between the TyG index and the risk of CAP in CHD patients according to different glucose metabolism states, with the highest OR value observed for DM (OR: 1.36; 95% CI 1.26–1.46). Taking the Q1 as a reference, Q4 was significantly associated with an increased risk of CAP during the DM.
Table 5
Association between TyG index and the risk of carotid artery plaques according to glucose regulation state
Glucose regulation state
Variables
Carotid artery plaques
OR (95% CI)a
P-value
OR (95% CI)b
P-value
OR (95% CI)c
P-value
Normal glucose regulation
TyG index
0.95 (0.90–1.01)
0.080
1.16 (1.09–1.24)
 < 0.001
1.11 (1.02–1.22)
0.017
Q1
Reference
 
Reference
 
Reference
 
Q2
0.98 (0.92–1.05)
0.526
1.11 (1.03–1.19)
0.007
1.04 (0.95–1.13)
0.412
Q3
0.94 (0.86–1.02)
0.112
1.18 (1.08–1.29)
 < 0.001
1.03 (0.93–1.15)
0.563
Q4
0.81 (0.71–0.92)
0.001
1.11 (0.97–1.28)
0.129
1.11 (0.93–1.32)
0.259
Prediabetes
TyG index
0.87 (0.82–0.92)
 < 0.001
1.06 (0.99–1.14)
0.078
1.08 (0.97–1.19)
0.182
Q1
Reference
 
Reference
 
Reference
 
Q2
0.90 (0.83–0.99)
0.032
1.06 (0.96–1.17)
0.288
0.94 (0.85–1.05)
0.295
Q3
1.02 (0.93–1.12)
0.645
1.23 (1.11–1.37)
 < 0.001
1.06 (0.94–1.20)
0.330
Q4
0.69 (0.62–0.77)
 < 0.001
0.99 (0.88–1.12)
0.879
0.90 (0.76–1.06)
0.202
Diabetes
TyG index
1.16 (1.11–1.22)
 < 0.001
1.36 (1.30–1.43)
 < 0.001
1.36 (1.26–1.46)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
1.11 (0.97–1.28)
0.142
1.26 (1.09–1.47)
0.003
1.13 (0.96–1.33)
0.147
Q3
1.18 (1.03–1.35)
0.017
1.37 (1.19–1.58)
 < 0.001
1.07 (0.91–1.25)
0.408
Q4
1.39 (1.22–1.58)
 < 0.001
1.87 (1.63–2.15)
 < 0.001
1.42 (1.21–1.66)
 < 0.001
aModel 1: unadjusted
bModel 2: adjusted for age, sex, SBP, DBP
cModel 3: adjusted for age, sex, SBP, DBP, CRP, TC, HDL-C, LDL-C, smoking, drinking, hypertension, hyperlipidemia, use of antihypertensives, and use of antilipidemic
This study also observed a significant association between TyG index and CAP risk in male patients with NGT (OR: 1.21; 95% CI 1.06–1.39). The association in females (OR: 1.45; 95% CI 1.32–1.60) with DM status was higher than in males (OR: 1.23; 95% CI 1.10–1.37) (Table 6). The association with CAP in CHD patients with DM status aged > 60 years old (OR: 1.35; 95% CI 1.24–1.48) with DM status was higher than those aged ≤ 60 years old (OR: 1.21; 95% CI 1.08–1.35) (Table 7).
Table 6
Association between the TyG index and the risk of carotid artery plaques according to different glucose regulation state and sex
Sex
Glucose regulation state
Variables
Carotid artery plaques
OR (95% CI)a
P-value
OR (95% CI)b
P-value
OR (95% CI)c
P-value
Male
Normal glucose regulation
TyG index
0.88 (0.81–0.96)
0.005
1.24 (1.13–1.36)
 < 0.001
1.21 (1.06–1.39)
0.005
Q1
Reference
 
Reference
 
Reference
 
Q2
0.98 (0.88–1.10)
0.751
1.23 (1.09–1.38)
0.001
1.06 (0.93–1.21)
0.398
Q3
0.79 (0.69–0.90)
 < 0.001
1.10 (0.96–1.27)
0.182
0.83 (0.70–0.96)
0.033
Q4
0.57 (0.48–0.68)
 < 0.001
1.00 (0.82–1.22)
0.974
0.91 (0.69–1.19)
0.494
Prediabetes
TyG index
0.67 (0.61–0.74)
 < 0.001
0.97 (0.87–1.07)
0.505
0.95 (0.82–1.12)
0.557
Q1
Reference
 
Reference
 
Reference
 
Q2
0.94 (0.81–1.10)
0.420
1.05 (0.89–1.24)
0.552
0.94 (0.79–1.12)
0.511
Q3
0.85 (0.73–0.99)
0.038
1.18 (1.00–1.39)
0.055
1.02 (0.84–1.23)
0.846
Q4
0.49 (0.42–0.58)
 < 0.001
0.83 (0.69–1.00)
0.045
0.67 (0.52–0.86)
0.002
Diabetes
TyG index
0.91 (0.84–0.97)
0.005
1.11 (1.03–1.19)
0.009
1.23 (1.10–1.37)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
0.99 (0.78–1.24)
0.904
1.19 (0.94–1.51)
0.143
1.13 (0.88–1.45)
0.331
Q3
1.06 (0.85–1.32)
0.592
1.34 (1.07–1.67)
0.011
1.13 (0.90–1.44)
0.284
Q4
0.98 (0.79–1.20)
0.821
1.48 (1.19–1.84)
 < 0.001
1.37 (1.08–1.74)
0.010
Female
Normal glucose regulation
TyG index
1.05 (0.97–1.14)
0.198
1.09 (1.00–1.19)
0.046
1.02 (0.90–1.15)
0.794
Q1
Reference
 
Reference
 
Reference
 
Q2
1.06 (0.97–1.15)
0.223
1.04 (0.94–1.14)
0.469
1.01 (0.91–1.23)
0.825
Q3
1.17 (1.06–1.30)
0.003
1.22 (1.09–1.37)
0.001
1.16 (1.01–1.33)
0.043
Q4
1.03 (0.86–1.24)
0.739
1.23 (1.01–1.5)
0.041
1.22 (0.95–1.56)
0.115
Prediabetes
TyG index
1.05 (0.97–1.14)
0.244
1.14 (1.04–1.24)
0.005
1.17 (1.02–1.35)
0.023
Q1
Reference
 
Reference
 
Reference
 
Q2
0.94 (0.84–1.06)
0.327
1.05 (0.93–1.20)
0.410
0.93 (0.81–1.07)
0.336
Q3
1.22 (1.08–1.38)
0.001
1.26 (1.11–1.44)
 < 0.001
1.10 (0.94–1.29)
0.222
Q4
0.89 (0.77–1.03)
0.127
1.12 (0.96–1.31)
0.145
1.12 (0.89–1.40)
0.328
Diabetes
TyG index
1.44 (1.35–1.53)
 < 0.001
1.58 (1.48–1.69)
 < 0.001
1.45 (1.32–1.60)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
1.31 (1.08–1.59)
0.005
1.30 (1.06–1.59)
0.012
1.14 (0.91–1.42)
0.261
Q3
1.44 (1.21–1.73)
 < 0.001
1.38 (1.14–1.67)
0.001
1.01 (0.82–1.25)
0.930
Q4
1.97 (1.65–2.34)
 < 0.001
2.15 (1.78–2.58)
 < 0.001
1.42 (1.14–1.77)
0.002
aModel 1: unadjusted
bModel 2: adjusted for age, SBP, DBP
cModel 3: adjusted for age, SBP, DBP, CRP, TC, HDL-C, LDL-C, smoking, drinking, hypertension, hyperlipidemia, use of antihypertensives, and use of antilipidemic
Table 7
Association between the TyG index and the risk of carotid artery plaques according to different glucose regulation state and age
Age
Glucose regulation state
Variables
carotid artery plaques
OR (95% CI)a
P-value
OR (95% CI)b
P-value
OR (95% CI)c
P-value
 ≤ 60
Normal glucose regulation
TyG index
1.32 (1.22–1.44)
 < 0.001
1.16 (1.06–1.28)
 < 0.001
1.12 (0.98–1.28)
0.099
Q1
Reference
 
Reference
 
Reference
 
Q2
1.27 (1.14–1.43)
 < 0.001
1.24 (1.10–1.40)
 < 0.001
1.17 (1.02–1.33)
0.026
Q3
1.53 (1.34–1.74)
 < 0.001
1.40 (1.22–1.60)
 < 0.001
1.24 (1.04–1.46)
0.015
Q4
1.38 (1.15–1.64)
 < 0.001
1.09 (0.91–1.32)
0.360
1.11 (0.86–1.43)
0.430
Prediabetes
TyG index
1.05 (0.96–1.15)
0.290
0.99 (0.90–1.09)
0.770
0.93 (0.80–1.09)
0.367
Q1
Reference
 
Reference
 
Reference
 
Q2
0.86 (0.73–1.02)
0.090
0.92 (0.77–1.09)
0.320
0.74 (0.61–0.90)
0.002
Q3
1.21 (1.02–1.43)
0.030
1.12 (0.94–1.34)
0.190
0.86 (0.70–1.05)
0.141
Q4
1.08 (0.91–1.29)
0.390
1.04 (0.87–1.26)
0.650
0.89 (0.69–1.15)
0.374
Diabetes
TyG index
1.21 (1.13–1.30)
 < 0.001
1.16 (1.08–1.25)
 < 0.001
1.21(1.08–1.35)
0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
1.32 (0.98–1.78)
0.070
1.23 (0.91–1.67)
0.190
0.90 (0.64–1.26)
0.544
Q3
1.71 (1.29–2.27)
 < 0.001
1.49 (1.11–2.00)
0.010
0.95 (0.68–1.31)
0.738
Q4
1.98 (1.51–2.60)
 < 0.001
1.69 (1.27–2.24)
 < 0.001
1.03 (0.74–1.43)
0.866
 > 60
Normal glucose regulation
TyG index
0.94 (0.87–1.02)
0.160
1.05 (0.96–1.14)
0.300
0.99 (0.88–1.11)
0.817
Q1
Reference
 
Reference
 
Reference
 
Q2
0.94 (0.86–1.03)
0.200
1.01 (0.92–1.11)
0.780
0.94 (0.85–1.04)
0.241
Q3
0.85 (0.76–0.95)
 < 0.001
0.99 (0.88–1.11)
0.890
0.87 (0.76–1.00)
0.048
Q4
0.90 (0.74–1.10)
0.320
0.95 (0.77–1.17)
0.640
0.90 (0.70–1.16)
0.420
Prediabetes
TyG index
0.98 (0.90–1.07)
0.640
1.03 (0.94–1.13)
0.510
0.96 (0.84–1.10)
0.568
Q1
Reference
 
Reference
 
Reference
 
Q2
1.03 (0.91–1.15)
0.680
1.08 (0.96–1.21)
0.230
0.97 (0.85–1.11)
0.686
Q3
1.09 (0.97–1.23)
0.150
1.19 (1.05–1.35)
0.010
1.01 (0.87–1.17)
0.916
Q4
0.76 (0.66–0.88)
 < 0.001
0.80 (0.69–0.94)
0.010
0.65 (0.52–0.80)
 < 0.001
Diabetes
TyG index
1.38 (1.29–1.47)
 < 0.001
1.43 (1.34–1.53)
 < 0.001
1.35 (1.24–1.48)
 < 0.001
Q1
Reference
 
Reference
 
Reference
 
Q2
1.18 (0.99–1.40)
0.060
1.25 (1.05–1.49)
0.010
1.19 (0.99–1.43)
0.059
Q3
1.15 (0.98–1.35)
0.080
1.25 (1.06–1.47)
0.010
1.05 (0.88–1.25)
0.618
Q4
1.63 (1.39–1.90)
 < 0.001
1.78 (1.52–2.09)
 < 0.001
1.45 (1.21–1.74)
 < 0.001
aModel 1: unadjusted
bModel 2: adjusted for sex, SBP, DBP
cModel 3: adjusted for sex, SBP, DBP, CRP, TC, HDL-C, LDL-C, smoking, drinking, hypertension, hyperlipidemia, use of antihypertensives, and use of antilipidemic

Discussion

The results of this study revealed a significant association between the TyG index and CAP in CHD patients. This is the first large-scale study to demonstrate this relationship between the TyG index and CAP in CHD patients, and assessed this relationship according to sex, ages and glucose metabolism states.
Studies in recent years have shown the close relationship between the TyG index and the homeostasis model assessment of insulin resistance (HOMA-IR). And the predictive value of the TyG index for IR was better than that for HOMA-IR [19]. Therefore, the TyG index reflect the indicator of peripheral IR. A cross-sectional study reported that the TyG index was positively associated with the prevalence of CAD and could be used as a marker of AS [28]. Compared to patients with the lowest the TyG index, those in the quartile with the highest TyG index have a higher risk of stroke and myocardial infarction (MI) [29]. The TyG index was also significantly associated with the progression of arterial stiffness in hypertensive people but not prehypertensive individuals [30]. The TyG index was also closely related to coronary artery calcification and carotid AS [31]. This finding is consistent with the results of the present study. The related mechanism of action may involve several aspects. Firstly, insulin can cause lipid hyaluronic degeneration by enhancing sympathetic nerve activity or acting as a growth factor. Lipohyaline deposition can block small arteries, leading to the development of CVD [32]. Secondly, the TyG index is associated with inflammation. IR can induce inflammation, oxidative stress, and metabolic changes, causing damage to the vascular endothelium due to inflammation [33]. Therefore, the TyG index in CHD patients was associated with the occurrence of CAP, in which a high level of TyG index was associated with the occurrence of higher CAP.
The close association between the TyG index and cerebral small vessel disease (cSVD) may be caused by other concomitant metabolic syndromes. IR patients usually have other comorbidities, including hypertension, DM and obesity [13, 34]. The TyG index has received attention in the field of DM and metabolism, and has a positive impact on the assessment and prediction of IR and metabolic syndrome in DM patients. A higher TyG index was associated with an increased risk of coronary artery stenosis in asymptomatic T2DM patients [35]. However, cardiometabolic heterogeneity in non-DM individuals has been reported [36, 37]. Consistent with the results of this study, this study observed a significant association between the TyG index in CHD patients and the risk of CAP according to glucose metabolism states and after adjusting for confounding variables, with the highest OR value observed for DM.
Recent studies have shown that female have a lower risk of cardiovascular disease compared to male, but that hyperglycemia and hyperinsulinemia caused by IR may reverse this sex-based protection. All insulin replacement markers showed that good association with HOMA-IR of both sexes, and the association between female and HOMA-IR was stronger than that of male [38]. However, some studies have found that there was no sex difference between the TyG index and MACEs in patients with hypertension [39]. There has been an investigation of the association between the TyG index and the early stages of subclinical atherosclerosis (SA) between the sexes. A high TyG index was independently associated with SA in non-diabetic female, but in NGT male. Regardless of sex, the TyG index is unrelated to the presence of SA in DM patients [40]. Higher TG and blood pressure had greater impact in both DM patients and those with NGT. Moreover, the number of CVD events and deaths was higher in female than that in male [41]. Consistent with the results of this study, the TyG index in female was more highly associated with CAP compared to the association in male. A high TyG index showed a higher association with CAP.
In the middle-aged and elderly populations, an increase in the TyG index was significantly associated with hypertension and isolated systolic hypertension [42]. This study showed that the OR value of middle-aged patients with CHD was higher than that of elderly patients with CHD. The TyG index was significantly related to the risk of CAP in middle-aged patients with NGT, whereas the TyG index was significantly related to the risk of CAP in elderly patients with DM. This may be because this study is a CHD population, with an average age of over 60 years old, belonging to the middle-aged and elderly population, and there is a certain bias for age. Therefore, future research should inclued people of different ages to determine the association between the TyG index and CAP according to ages.
To sum up, with an increasing number of studies on the influence of the TyG index on patients with cardiovascular diseases, the clinical significance of the TyG index is becoming increasingly clear. Evaluation of the TyG index may have important clinical significance for risk stratification and individualized treatment of CHD patients.

Strengths and limitations

This large-scale, multi-center cohort study had several limitations. First, this study was a multi-center study, thus, there may be bias in the measurement methods at different research centers. However, the practitioners conducted external quality assessments between clinical laboratories in each center. Second, this study was a cross-sectional study. Therefore, the results of this study cannot establish causality. The exact mechanism of the relationship between the TyG index and CAP requires further prospective large-scale research.

Conclusion

This study demonstrated a significant association between the TyG index and CAP in CHD patients. In addition, the association between the TyG index and CAP in CHD patients was higher in female than in male, and higher in middle-aged and elderly than in the elderly. In DM patients, the association between the TyG index and CAP in CHD patients was higher. As a marker of IR, the TyG index is easy to calculate and may reflect the risk of CAP in CHD patients. The results of this study may emphasize the need for a risk management strategy for specific sex and different age groups to prevent the occurrence of CAP in CHD patients.

Acknowledgements

We thank all the participants in the study and the members of the survey teams, and the groups providing financial support.

Declarations

This study was approved by the ethics committee of Tianjin University of Traditional Chinese Medicine (TJUTCM-EC20190008) and registered in the Chinese Clinical Trial Registry (ChiCTR-1900024535) and in ClinicalTrials.gov (NCT04026724).
Not applicable.

Competing interests

The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
4.
Zurück zum Zitat Juárez-Rojas JG, Posadas-Romero C, Martínez-Alvarado R, Jorge-Galarza E, Reyes-Barrera J, Sánchez-Lozada LG, Torres-Tamayo M, Medina-Urrutia AX. Type 2 diabetes mellitus is associated with carotid artery plaques in patients with premature coronary heart disease. Rev Invest Clin. 2018;70(6):301–9. https://doi.org/10.24875/RIC.18002591.CrossRefPubMed Juárez-Rojas JG, Posadas-Romero C, Martínez-Alvarado R, Jorge-Galarza E, Reyes-Barrera J, Sánchez-Lozada LG, Torres-Tamayo M, Medina-Urrutia AX. Type 2 diabetes mellitus is associated with carotid artery plaques in patients with premature coronary heart disease. Rev Invest Clin. 2018;70(6):301–9. https://​doi.​org/​10.​24875/​RIC.​18002591.CrossRefPubMed
8.
Zurück zum Zitat Jin JL, Cao YX, Zhang HW, Sun D, Hua Q, Li YF, Guo YL, Wu NQ, Zhu CG, Gao Y, Dong QT, Liu HH, Dong Q, Li JJ. Lipoprotein(a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes. Diabetes Care. 2019;42(7):1312–8. https://doi.org/10.2337/dc19-0274.CrossRefPubMed Jin JL, Cao YX, Zhang HW, Sun D, Hua Q, Li YF, Guo YL, Wu NQ, Zhu CG, Gao Y, Dong QT, Liu HH, Dong Q, Li JJ. Lipoprotein(a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes. Diabetes Care. 2019;42(7):1312–8. https://​doi.​org/​10.​2337/​dc19-0274.CrossRefPubMed
19.
Zurück zum Zitat Irace C, Carallo C, Scavelli FB, De Franceschi MS, Esposito T, Tripolino C, Gnasso A. Markers of insulin resistance and carotid atherosclerosis. A comparison of the homeostasis model assessment and triglyceride glucose index. Int J Clin Pract. 2013;67(7):665–72. https://doi.org/10.1111/ijcp.12124.CrossRefPubMed Irace C, Carallo C, Scavelli FB, De Franceschi MS, Esposito T, Tripolino C, Gnasso A. Markers of insulin resistance and carotid atherosclerosis. A comparison of the homeostasis model assessment and triglyceride glucose index. Int J Clin Pract. 2013;67(7):665–72. https://​doi.​org/​10.​1111/​ijcp.​12124.CrossRefPubMed
20.
Zurück zum Zitat Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, Ratchford EV, Sarna L, Stecker EC, Wiggins BS. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018;72(25):3332–65. https://doi.org/10.1016/j.jacc.2018.10.027.CrossRefPubMed Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, Ratchford EV, Sarna L, Stecker EC, Wiggins BS. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018;72(25):3332–65. https://​doi.​org/​10.​1016/​j.​jacc.​2018.​10.​027.CrossRefPubMed
28.
Zurück zum Zitat Won KB, Lee BK, Park HB, Heo R, Lee SE, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Sung JM, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Chun EJ, Cademartiri F, Maffei E, Marques H, de Araújo GP, Leipsic JA, Shin S, Choi JH, Virmani R, Samady H, Chinnaiyan K, Raff GL, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK, Chang HJ. Quantitative assessment of coronary plaque volume change related to triglyceride glucose index: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry. Cardiovasc Diabetol. 2020;19(1):113. https://doi.org/10.1186/s12933-020-01081-w.CrossRefPubMedPubMedCentral Won KB, Lee BK, Park HB, Heo R, Lee SE, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Sung JM, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Chun EJ, Cademartiri F, Maffei E, Marques H, de Araújo GP, Leipsic JA, Shin S, Choi JH, Virmani R, Samady H, Chinnaiyan K, Raff GL, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK, Chang HJ. Quantitative assessment of coronary plaque volume change related to triglyceride glucose index: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography IMaging (PARADIGM) registry. Cardiovasc Diabetol. 2020;19(1):113. https://​doi.​org/​10.​1186/​s12933-020-01081-w.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22. https://doi.org/10.1016/S0140-6736(10)60484-9.CrossRef Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22. https://​doi.​org/​10.​1016/​S0140-6736(10)60484-9.CrossRef
Metadaten
Titel
Association between triglyceride glucose index and carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China
verfasst von
Zhu Li
Yuanyuan He
Shuo Wang
Lin Li
Rongrong Yang
Yijia Liu
Qi Cheng
Lu Yu
Yanchao Zheng
Hongmei Zheng
Shan Gao
Chunquan Yu
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Cardiovascular Diabetology / Ausgabe 1/2022
Elektronische ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-022-01470-3

Weitere Artikel der Ausgabe 1/2022

Cardiovascular Diabetology 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.